<DOC>
	<DOCNO>NCT01597388</DOCNO>
	<brief_summary>The purpose study assess safety tolerability AZD2014 give combination Fulvestrant .</brief_summary>
	<brief_title>AZD2014 Fulvestrant Patients With ER+ Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>A Phase I , Open-label , Multicentre , Study Assess Safety , Tolerability , Pharmacokinetics Preliminary Efficacy AZD2014 Administered Orally Combination Intramuscular ( IM ) Fulvestrant Patients Estrogen Receptor Positive ( ER+ ) Advanced , Metastatic Breast Cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Provision sign date write informed consent prior study specific procedure , sample analysis Aged least 18 At least one lesion ( measurable and/or nonmeasurable ) accurately assessed baseline computerise tomography ( CT ) magnetic resonance imaging ( MRI ) plain Xray suitable repeat assessment Histological cytological confirmation ER+ advance metastatic breast cancer tumour eligible treatment fulvestrant Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patients must evidence nonchildbearing potential . Prior chemotherapy , biological therapy , radiation therapy , androgen , thalidomide , immunotherapy , anticancer agent , investigational agent within 14 day start study treatment ( include palliative radiotherapy focal site ) Major surgery within 4 week prior entry study ( exclude placement vascular access ) , minor surgery within 2 week entry study . Patients severe cardiac condition ischemia , impair ventricular function arrhythmia , evidence severe uncontrolled systemic current unstable uncompensated respiratory cardiac condition . Patients diabetes type 1 uncontrolled type II ( HbA1c &gt; 8 % assess locally )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Estrogen receptor positive</keyword>
	<keyword>Advanced metastatic breast cancer</keyword>
	<keyword>Estrogen receptor positive advance metastatic breast cancer</keyword>
</DOC>